Comorbid pathology and mechanisms of development of atherosclerosis with in-stent restenosis in ischemic heart disease after percutaneous transluminal coronary angioplasty (review)
Year: 2022, volume 18 Issue: №3 Pages: 354-359
Heading: Cardiology Article type: Review
Authors: Meshkova M.A., Starodubtseva I.A.
Organization: Voronezh State Medical University n.a. N.N. Burdenko
Heading: Cardiology Article type: Review
Authors: Meshkova M.A., Starodubtseva I.A.
Organization: Voronezh State Medical University n.a. N.N. Burdenko
Summary:
In-stent restenosis (ISR) is the most unfavorable complication of interventional treatment of coronary heart disease. The main pathogenetic mechanisms of this complication are neointimal hyperplasia and neoatherosclerosis. Concomitant pathology can provoke the mentioned processes increasing the probability of restenosis formation. Objective: comprehensive coverage of the main issues of comorbidity influence on the risk of coronary artery restenosis after percutaneous transluminal coronary angioplasty. Literature search was performed in PubMed, Google Scholar, Scopus, Web of Science, eLibrary, including original studies in the period from 2006 to 2021. A total of 37849 articles were initially found in the above databases by the fact of keyword mention; 32 most significant papers were included in the review as a result of using the exclusion criteria. The influence of obesity, diabetes mellitus on the risk of ISR was demonstrated.
Bibliography:
1. Chernyak AA, Deshko MS, Snezhitsky VA, et al. Percutaneous coronary interventions — the current state of the issue: evolution of stents. Journal of the Grodno State Medical University 2020; 18 (4): 365-74. DOI: 10.25 298/2221 -8785-2020-18-4-365-374.
2. Smirnov КА, Biryukov AV, Ivanchenko RD, et al. History of development and comparative evaluation of modern stents for coronary arteries. Circulation Pathology and Cardiac Surgery 2019; 23 (1 Suppl. 1): 9-17. DOI: 10.21688-1681-3472-2019-1S-S9-S17.
3. Dygai AM. On the issue of antiproliferative coating of coronary stents. Circulation Pathology and Cardiac Surgery 2018; 22 (2): 22-9. DOI: 10.21688/1681-3472-2018-2-22-29.
4. Shlofmitz Е, Case ВС, Chen Y, et al. Classification of restenosis by Waxman in a stent: a mechanism-based approach to the treatment of restenosis. Cardiovasc Revasc Med 2021; (33): 62-7. DOI: 10.1016/j.carrev.2021.06.004.
5. De Gregorio J, Tateishi K. Non-extensible restenosis in the stent: an ounce of prevention. Cardiovasc Revasc Med 2022; (34): 38-9. DOI: 10.1016/j.carrev.2021.10.018.
6. Urban P, Gershlick AH, Guagliumi G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006; 113 (11): 1434-41. DOI: 10.1161/CIRCULATIONAHA.104.532242.
7. Joner M, Finn AV, Farb A, et al. Pathology of drug-elut-ing stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48 (1): 193-202. DOI: 10.1016/j. jacc.2006.03.042.
8. Otsuka F, Byrne RA, Yahagi K, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intra-vascular imaging assessment. European Heart Journal 2015; 36 (32): 2147-59. DOI: 10.1093/eurheartj/ehv205.
9. Lee S-J, Choi D-W, Suh Y, et al. Long-term clinical outcomes between biodegradable and durable polymer drug-eluting stents: A nationwide cohort study. Front Cardiovasc Med 2022; (9): 873114. DOI: 10.3389/fcvm.2022.873114.
10. Barbarash OL, Voyevoda Ml, Galstyan GR, et al. Pre-dia-betes as an interdisciplinary problem: definition, risks, approaches to the diagnostics and prevention of type 2 diabetes and cardiovascular complications. Russian Journal of Cardiology 2019; (4): 83-91. DOI: 10.15829/1560-4071 -2019-4-83-91.
11. Batalina MV, Fedyunina VA, Batalin VA, et al. The ne-phrological aspects of acute coronary syndrome. Orenburg Medical Herald2019; 7; 1 (25): 14-9.
12. Cheng G, Chang FJ, Wang Y, et al. Factors influencing stent restenosis after percutaneous coronary intervention in patients with coronary heart disease: A clinical trial based on 1 -year follow-up. Medical science monitor: international medical journal of experimental and clinical research 2019; (25): 240-7. DOI: 10.12659/MSM. 908692.
13. Veselovskaya NG, Chumakova GA, Shenina NN, et al. Predictors of coronary artery restenosis after stent-ing in obese women. Russian Journal of Cardiology 2014; (9): 31-6. DOI: 10.12659/MSM.908692.
14. Li MF, Zhao CC, Li TT, et al. The coexistence of carotid and lower extremity atherosclerosis further increases car-dio-cerebrovascular risk in type 2 diabetes. Cardiovascular Dia-betology2016; (15): 43. DOI: 10.1186/s12933-016-0360-2.
15. Frobert O, Lagerqvist B, Carlsson J, et al. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol 2009; 53(18): 1660-7. DOI: 10.1016/j.jacc.2009.01.054.
16. Xu S, Wang B, Liu W The effects of insulin therapy on mortality in diabetic patients undergoing percutaneous coronary intervention. Ann Transl Med 2021; 9 (16): 1294. DOI: 10.21037/atm-21 -1911.
17. Barbarash OL, Kashtalap VV Managing the risk of ischemic events in patients with multifocal atherosclerosis and type 2 diabetes mellitus 2020; (1): 34-44. DOI: 10.215 18/2307-1109-2020-1 -34-44.
18. Gabbasov ZA, Kozlov SG, Byazrova SV, et al. Relationship between the level of circulating CD45+ platelets and development of restenosis after implantation of drug-eluting stents to patients with coronary heart disease. Bulletin of Experimental Biology and Medicine 2016; 162 (10): 528-32. DOI: 10.1007/S10517-017-3653-х.
19. Naumova LA, Osipova ON. Comorbidity: mechanisms of pathogenesis, clinical significance. Modern Problems of Science and Education 2016; (5). URL: https://science-education.ru/ru/ar-ticle/view?id=25301 (29 July 2022).
20. Zotz RJ, Dietz W, Lindemann S, Gent-Zotz S. Coronary restenosis. Hertz 2019; 44 (1): 35-9. [German.] DOI: 10.1007/S00059-018-4777-0.
21. Zhu F, Zuo L, Hu R, et al. A ten-genes-based diagnostic signature for atherosclerosis. ВМС Cardiovasc Disord 2021; 21 (1): 513. DOI: 10.1186/s12872-021-02323-9.
22. Barbarash OL, Kashtalap VV. A patient with ischemic heart disease and multifocal atherosclerosis. How to optimize the forecast? Medical Council 2018; (16): 32-8. DOI: 10.21518/2079-701Х-2018-16-32-38.
23. NusM, MallatZ. Immune-mediated mechanisms of atherosclerosis and implications for the clinic. Expert Rev Clin Immunol 2016; 12 (11): 1217-37. DOI: 10. 1080/1744666X.2016. 1195686.
24. Johnson JL. Metalloproteinases in atherosclerosis. Eur J Pharmacol 2017; (816): 93-106. DOI: 10.1016/j.ejphar. 2017.09.007.
25. Cancel LM, Ebong ЕЕ, Mensah S, et al. Endothelial gly-cocalyx, apoptosis and inflammation in an atherosclerotic mouse model. Atherosclerosis 2016; (252): 136-46. DOI: 10.1016/j. atherosclerosis.2016.07.930.
26. Gromova OA, Torshin lYu, Lila AM, et al. Prevention of restenosis in patients after percutaneous coronary intervention: possible pathogenetic approach. Russian Medical Journal 2019; 8 (I): 33-40.
27. Ebert ML, Schmidt VF, Pfaff L, et al. Animal models of neointimal hyperplasia and restenosis: species-specific differences and implications for translational research. JACC Basic Transl Sci 2021; 6 (11); 900-17. DOI: 10.1016/j.jacbts.2021.06.006.
28. Wun K, Theriault BR, Pierre JF, et al. Microbiota control acute arterial inflammation and neointimal hyperplasia develop-
merit after arterial injury. PLoS ONE 2018; 13 (12). e0208426. DOI: 10.1371 /journal, pone.0208426.
29. Chen EB, Shapiro KE, Wun K, et al. Microbial colonization of germ-free mice restores neointimal hyperplasia development after arterial injury. J Am Heart Assoc 2020; 9 (5): e013496. DOI: 10.1161/JAHA.119.013496.8
30. Ma J, Li H. The role of gut microbiota in atherosclerosis and hypertension. Front Pharmacol 2018; (9): 1082. DOI: 10.3389/fphar.2018.01082.
31. Komiyama H, Takano M, Hata N, et al. Neoatheroscle-rosis: coronary stents seal atherosclerotic lesions but result in making a new problem of atherosclerosis. World J Cardiol 2015; 7(11): 776-83. DOI: 10.4330/wjc.v7.i11.776.
32. Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014. Eur Heart J 2015; 36 (47): 3320-31. DOI: 10.1093/eurheartj/ehv511.
| Attachment | Size |
|---|---|
| 2022_3_354-359.pdf | 410.03 KB |
Русский
English